分红方面，优宁维A股上市后累计派现1.82亿元。近三年，累计派现1.38亿元。 机构持仓方面，截止2025年9月30日，优宁维十大流通股东中，诺安多策略混合A（320016）位居第八 大流通股东，持股49.91万股，为新进股东。 融券方面，优宁维1月22日融券偿还0.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00元；融 券余量0.00股，融券余额0.00元，超过近一年90%分位水平，处于高位。 资料显示，上海优宁维生物科技股份有限公司位于上海市浦东新区古丹路15弄16号楼，成立日期2004年 10月22日，上市日期2021年12月28日，公司主营业务涉及面向高等院校、科研院所、医院和生物医药企 业等,提供以抗体为核心的生命科学试剂及相关仪器、耗材和综合技术服务。主营业务收入构成为：生 命科学试剂77.94%，生命科学仪器及耗材16.11%，综合技术服务5.95%。 截至9月30日，优宁维股东户数9893.00，较上期减少13.19%；人均流通股5753股，较上期增加15.19%。 2025年1月-9月，优宁维实现营业收入7.76亿元，同比减少6.24%；归母净利润-1507.96万元，同比减少 ...

Group 1 - The core viewpoint of the news is that You Ning Wei's stock performance and financing activities indicate a high level of investor interest, despite a decline in revenue and profit [1][2]. - As of December 24, You Ning Wei's stock price increased by 0.60%, with a trading volume of 17.13 million yuan, and a net financing purchase of 287,600 yuan [1]. - The total financing and securities balance for You Ning Wei reached 63.36 million yuan, accounting for 2.44% of its market capitalization, which is above the 90th percentile of the past year [1]. Group 2 - As of September 30, the number of shareholders for You Ning Wei decreased by 13.19% to 9,893, while the average circulating shares per person increased by 15.19% to 5,753 shares [2]. - For the period from January to September 2025, You Ning Wei reported a revenue of 776 million yuan, a year-on-year decrease of 6.24%, and a net profit attributable to shareholders of -15.08 million yuan, a decline of 207.11% [2]. - Since its A-share listing, You Ning Wei has distributed a total of 182 million yuan in dividends, with 138 million yuan distributed in the last three years [3].

Group 1 - The core viewpoint of the news is that You Ning Wei's stock performance and financial metrics indicate a challenging period, with a decline in revenue and net profit, while financing activities show a high level of engagement from investors [1][2][3] Group 2 - As of December 23, You Ning Wei's stock price decreased by 0.17%, with a trading volume of 12.67 million yuan. The financing buy-in amount was 1.24 million yuan, while the net financing buy-in was 399,400 yuan [1] - The total financing and securities lending balance for You Ning Wei reached 63.08 million yuan, accounting for 2.44% of the circulating market value, indicating a high level compared to the past year [1] - The company reported a revenue of 776 million yuan for the first nine months of 2025, a year-on-year decrease of 6.24%, and a net profit attributable to shareholders of -15.08 million yuan, a significant decline of 207.11% [2] - The company has distributed a total of 182 million yuan in dividends since its A-share listing, with 138 million yuan distributed in the last three years [3] - As of September 30, 2025, the number of shareholders decreased by 13.19% to 9,893, while the average circulating shares per person increased by 15.19% to 5,753 shares [2][3]

Core Insights - The stock of Uningwei increased by 1.19% on November 12, with a trading volume of 51.13 million yuan [1] - The company experienced a net financing outflow of 2.28 million yuan on the same day, indicating a low financing balance compared to the past year [1] - Uningwei's main business includes providing life science reagents, instruments, and technical services, with a revenue composition heavily weighted towards life science reagents [1] Financing and Trading Data - On November 12, Uningwei had a financing buy-in amount of 3.43 million yuan and a financing repayment of 5.71 million yuan, resulting in a net financing buy of -2.28 million yuan [1] - The total financing and securities lending balance as of November 12 was 56.88 million yuan, accounting for 1.98% of the circulating market value, which is below the 50th percentile of the past year [1] - Uningwei had no securities lending activity on November 12, with a lending balance of 0.00 shares, indicating a high level of inactivity in this area [1] Financial Performance - For the period from January to September 2025, Uningwei reported a revenue of 776 million yuan, a year-on-year decrease of 6.24%, and a net profit attributable to shareholders of -15.08 million yuan, a significant decline of 207.11% [2] - As of September 30, 2025, the number of Uningwei's shareholders was 9,893, a decrease of 13.19% from the previous period, while the average circulating shares per person increased by 15.19% to 5,753 shares [2] Dividend and Shareholding Information - Since its A-share listing, Uningwei has distributed a total of 182 million yuan in dividends, with 138 million yuan distributed over the past three years [3] - As of September 30, 2025, the top ten circulating shareholders included a new shareholder, Nuoan Multi-Strategy Mixed A, holding 499,100 shares, ranking as the eighth largest circulating shareholder [3]

Core Viewpoint - The company You Ning Wei has shown a mixed performance in terms of stock trading and financial results, with a notable decrease in revenue and net profit year-on-year, while maintaining a significant presence in the life sciences sector [1][2]. Group 1: Stock Performance - On November 11, You Ning Wei's stock rose by 1.27%, with a trading volume of 33.29 million yuan [1]. - The financing buy-in amount on the same day was 3.30 million yuan, while the financing repayment was 3.03 million yuan, resulting in a net financing buy of 0.28 million yuan [1]. - As of November 11, the total financing and securities balance was 59.16 million yuan, accounting for 2.08% of the market capitalization, indicating a high level compared to the past year [1]. Group 2: Financial Performance - For the period from January to September 2025, You Ning Wei reported a revenue of 776 million yuan, representing a year-on-year decrease of 6.24% [2]. - The net profit attributable to the parent company was -15.08 million yuan, reflecting a significant year-on-year decline of 207.11% [2]. Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders for You Ning Wei was 9,893, a decrease of 13.19% from the previous period [2]. - The average number of circulating shares per person increased by 15.19% to 5,753 shares [2]. - The company has distributed a total of 182 million yuan in dividends since its A-share listing, with 138 million yuan distributed in the last three years [3].

Core Viewpoint - The company You Ning Wei has shown a mixed performance in terms of stock trading and financial results, with a slight increase in stock price but a decline in revenue and net profit for the year-to-date period [1][2]. Group 1: Stock Performance - On November 6, You Ning Wei's stock price increased by 0.71%, with a trading volume of 25.51 million yuan [1]. - The financing buy-in amount on the same day was 2.51 million yuan, while the financing repayment was 2.12 million yuan, resulting in a net financing buy-in of 390,100 yuan [1]. - As of November 6, the total financing and securities lending balance was 58.33 million yuan, accounting for 2.06% of the circulating market value, indicating a relatively high level compared to the past year [1]. Group 2: Financial Performance - For the period from January to September 2025, You Ning Wei reported a revenue of 776 million yuan, representing a year-on-year decrease of 6.24% [2]. - The net profit attributable to the parent company was -15.08 million yuan, reflecting a significant year-on-year decline of 207.11% [2]. Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders for You Ning Wei was 9,893, a decrease of 13.19% from the previous period [2]. - The average number of circulating shares per shareholder increased by 15.19% to 5,753 shares [2]. - The company has distributed a total of 182 million yuan in dividends since its A-share listing, with 138 million yuan distributed over the past three years [3].

Company Overview - Shanghai Youningwei Biotechnology Co., Ltd. was established on October 22, 2004, and listed on December 28, 2021. The company is located at 15 Lane 16, Gudan Road, Pudong New District, Shanghai [1]. - The main business involves providing life science reagents centered on antibodies, related instruments, consumables, and comprehensive technical services to higher education institutions, research institutes, hospitals, and biopharmaceutical companies. The revenue composition is as follows: life science reagents 77.94%, life science instruments and consumables 16.11%, and comprehensive technical services 5.95% [1]. Financial Performance - As of September 30, 2025, the company achieved an operating income of 776 million yuan, a year-on-year decrease of 6.24%. The net profit attributable to the parent company was -15.08 million yuan, a year-on-year decrease of 207.11% [2]. - The company has distributed a total of 182 million yuan in dividends since its A-share listing, with 138 million yuan distributed in the past three years [3]. Stock Performance - On October 31, the stock price increased by 2.04%, reaching 32.00 yuan per share, with a trading volume of 25.75 million yuan and a turnover rate of 1.42%. The total market capitalization is 2.773 billion yuan [1]. - Year-to-date, the stock price has risen by 13.67%, with a 2.24% increase over the last five trading days, a 5.33% increase over the last 20 days, and a 3.53% decrease over the last 60 days [1]. Shareholder Information - As of September 30, 2025, the number of shareholders is 9,893, a decrease of 13.19% from the previous period. The average number of circulating shares per person is 5,753, an increase of 15.19% [2]. - Among the top ten circulating shareholders, the Noan Multi-Strategy Mixed A (320016) fund is the eighth largest shareholder, holding 499,100 shares as a new shareholder [3].

Group 1 - The core viewpoint of the news is that You Ning Wei's stock performance and financial metrics indicate a challenging period, with a decline in revenue and net profit, while financing activities show a relatively high level of engagement [1][2]. Group 2 - On September 25, You Ning Wei's stock price fell by 1.17%, with a trading volume of 31.80 million yuan. The financing buy-in amount was 2.18 million yuan, while the financing repayment was 1.93 million yuan, resulting in a net financing buy of 250,600 yuan. The total financing and securities balance reached 61.66 million yuan [1]. - The financing balance of You Ning Wei is 61.66 million yuan, accounting for 2.34% of the circulating market value, which is above the 70th percentile level over the past year, indicating a high position [1]. - As of June 30, the number of shareholders of You Ning Wei increased to 11,400, a rise of 5.02%, with an average of 4,994 circulating shares per person, up by 31.33% [2]. - For the first half of 2025, You Ning Wei reported operating revenue of 505 million yuan, a year-on-year decrease of 8.63%, and a net profit attributable to shareholders of -13.38 million yuan, a year-on-year decrease of 188.64% [2]. - Since its A-share listing, You Ning Wei has distributed a total of 182 million yuan in dividends, with 138 million yuan distributed over the past three years [3].

Group 1 - The core viewpoint of the news is that You Ning Wei's stock has experienced a decline, with significant changes in financing and shareholder metrics [1][2] - On August 27, You Ning Wei's stock fell by 4.29%, with a trading volume of 91.43 million yuan. The net financing buy was -3.55 million yuan, indicating a higher level of financing repayment compared to buying [1] - As of August 27, the total financing and securities lending balance for You Ning Wei was 52.22 million yuan, which is 1.86% of its market capitalization, indicating a low financing balance compared to the past year [1] Group 2 - As of June 30, the number of shareholders for You Ning Wei increased by 5.02% to 11,400, with an average of 4,994 circulating shares per person, up 31.33% [2] - For the first half of 2025, You Ning Wei reported a revenue of 505 million yuan, a year-on-year decrease of 8.63%, and a net profit attributable to shareholders of -13.38 million yuan, a significant decline of 188.64% [2] - Since its A-share listing, You Ning Wei has distributed a total of 182 million yuan in dividends, with 138 million yuan distributed over the past three years [3]